Drug Discovery

The notion of one-drug binding to one receptor to treat one disease is a dated concept. Using new bioinformatics and cheminfomatics techniques combined with systems biology we are at the beginning of an era when we can better predict the impact of a drug on the complete system. In principle this could lead to more and better drugs. This interview outlines some of these concepts which are to be discussed at the forthcoming Bio-IT Conference in Boston, USA see...

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.

Peter Amoako Yirenkyi from Kwame Nkrumah University in Kumasi, Ghana discusses his work in distributed computing for drug discovery at the ICTP workshop on Using Open Access Models for Scientific Dissemination

Andy McCammon discusses "Computational Science and Drug Discovery" at The Minority-Serving Institutions Cyberinfrastructure Institute (MSICI2) Preliminary Program at the San Diego Supercomputing Center, University of California San Diego La Jolla, California | June 26-29, 2006

Rommie Amaro, Computational and Theoretical Biophysical Chemist, discusses how she uses the resources at SDSC to conduct her drug discovery research on African Sleeping Sickness. Originally posted by SDSC on SDSC's CI Channel at: www.cichannel.org